Topic: glioblastoma multiforme (GBM)
Novocure named Pritesh Shah chief commercial officer, to lead the tumor-treating device manufacturer’s international business units.
The team behind a much-hyped cancer-killing virus reports an "encouraging" long-term survival rate in glioblastoma patients.
A modified form of poliovirus seems to shrink breast tumors by latching onto a protein that's heavily expressed on the surface of some cancer cells.
Northwest Bio unveiled interim phase 3 data showing its dendritic cell vaccine improved survival rates in patients with newly diagnosed glioblastoma.
CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.
Israeli biotech VBL Therapeutics has joined a long line of companies that have failed to move the needle against a form of aggressive brain tumor.
Targeting a "highly prevalent" antigen could address the heterogeneity of glioblastomas.
The funding will see Quentis' lead immunotherapy candidate into the clinic in 2019.
Researchers in the U.K. tested AstraZeneca’s PARP inhibitor Lynparza and found it can penetrate the blood-brain barrier and invade glioblastoma tumors.
Here is Monday's medtech news of note.